ReviewCancers2022
Gallbladder Cancer: Current Multimodality Treatment Concepts and Future Directions.
Review in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.
- Epidemiology of gall bladder cancer and its prevalence worldwide: a meta-analysis.Orphanet journal of rare diseases · 2025Pooled it
- Doublet versus triplet therapy in Indian patients with locally advanced & metastatic gall bladder cancer: a randomised trial.Scientific reports · 2026Trial
- Efficacy and Safety of First-Line Chemotherapy With Gemcitabine Plus Nab-Paclitaxel in Unresectable Gallbladder Cancer.Cancer medicine · 2026Article
- Article
- From Anatomical Staging to Precision Prognostication: Evolution of Gallbladder Cancer Staging Across AJCC Editions and the 2025 UICC TNM Update.Journal of personalized medicine · 2026Review
- Perioperative chemotherapy for clinical stage IIIB gallbladder cancer: a review of the National Cancer Database.International journal of clinical oncology · 2026Article
- Global burden landscape (1990-2021) of gallbladder and biliary tract cancer attributable to high body mass index in older adults and a projection to 2050.Journal of gastrointestinal oncology · 2026Article
- Gallbladder carcinoma in Brazil: Clinicopathological profile and survival outcomes from a high-volume cancer center.World journal of gastroenterology · 2026Article
- Temporal trends in the incidence and prognosis of lung metastasis in gallbladder cancer: risk stratification and survival analysis.American journal of cancer research · 2026Article
- Targeting E2F8 sensitizes gemcitabine-resistant gallbladder cancer to PARP inhibitors by disrupting RRM2-driven DNA repair.Journal of experimental & clinical cancer research : CR · 2025Article
- Individualized Prognostic Insights: CONUT-GBRS for Survival Prediction in Gallbladder Cancer.Cancer medicine · 2025Article
- Recent Trends in Surgical Strategies of Early-Stage Gallbladder Cancer: A Narrative Review.Journal of clinical medicine · 2025Review
- Single-cell analyses unravel ecosystem dynamics and intercellular crosstalk during gallbladder cancer malignant transformation.Hepatology communications · 2025Article
- Ganoderic acid a potentiates cisplatin's cytotoxicity on gallbladder cancer cells by promoting DNA damage and inhibiting cell stemness.World journal of surgical oncology · 2025Article
- Prognostic value of preoperative fibrinogen to albumin ratio in predicting postoperative outcomes in patients with gallbladder cancer.World journal of gastrointestinal surgery · 2025Article
- Endoscopic diagnosis and management of gallbladder carcinoma in minimally invasive era: New needs, new models.World journal of gastrointestinal oncology · 2024Article
- A Single-Center Analysis of Patient Characteristics and Overall Survival in Patients with Resectable Gallbladder Cancer.Healthcare (Basel, Switzerland) · 2024Article
- Repair of genomic interstrand crosslinks.DNA repair · 2024Review
- Parthenolide induces gallbladder cancer cell apoptosis via MAPK signalling.Annals of medicine and surgery (2012) · 2024Article
- Comparison of treatment models for single primary advanced gallbladder cancer.Frontiers in immunology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gallbladder cancer (GBC) is the most common primary tumor site of biliary tract cancer (BTC), accounting for 0.6% of newly diagnosed cancers and 0.9% of cancer-related deaths. Risk factors, including female sex, age, ethnic background, and chronic inflammation of the gallbladder, have been identified. Surgery is the only curative option for early-stage GBC, but only 10% of patients are primary eligible for curative treatment. After neoadjuvant treatment, up to one-third of locally advanced GBC patients could benefit from secondary surgical treatment. After surgery, only a high-risk subset of patients benefits from adjuvant treatment. For advanced-stage GBC, palliative chemotherapy with gemcitabine and cisplatin is the current standard of care in line with other BTCs. After the failure of gemcitabine and cisplatin, data for second-line treatment in non-resectable GBC is poor, and the only recommended chemotherapy regimen is FOLFOX (5-FU/folinic acid and oxaliplatin). Recent advances with the PD-L1 inhibitor durvalumab open the therapy landscape for immune checkpoint inhibition in GBC. Meanwhile, targeted therapy approaches are a cornerstone of GBC therapy based on molecular profiling and new evidence of molecular differences between different BTC forms and might further improve the prognosis of GBC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.